Lumos Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumos Pharma, Inc.
US incentive program would gain only four more years, despite calls for a permanent extension.
Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.
The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.
The US giant's chief patient officer and former head of the CDC, is proud of the "incredible collaboration" going on across the biopharmaceutical industry to tackle coronavirus but says "we have to be honest that we really don't understand this disease."
- Large Molecule
- Other Names / Subsidiaries
- BioProtection Systems Corporation (BPS)
- BlueLink Pharmaceuticals
- NewLink Genetics
- NewLink Genetics Corporation